Cold plasma is moving from a specialized scientific technology toward a broader commercial solution for healthcare, sterilization, food safety, electronics, textiles, and surface treatment. Unlike conventional high-temperature plasma, cold plasma operates without exposing treated materials to extreme heat. This makes it particularly attractive for applications involving heat-sensitive materials and biological tissues. Increasing concerns around hospital-acquired infections, chronic wounds, and the need for non-invasive treatment technologies are creating new opportunities for cold plasma systems.

According to Grand View Research, the global cold plasma market was valued at USD 167.8 million in 2025 and is estimated to reach USD 191.1 million in 2026. The market is projected to grow to USD 495.9 million by 2033, expanding at a CAGR of 14.6% from 2026 to 2033. The market's growth reflects rising healthcare demand as well as expanding industrial applications for non-thermal surface treatment and sterilization. 

Download a free sample copy of the Cold Plasma Market report to understand detailed coverage and inclusions in the final report

Why Cold Plasma Is Attracting Attention

Cold plasma, also referred to as non-equilibrium plasma, is a partially ionized gas containing reactive species that can interact with microorganisms, surfaces, and biological tissues. Because the process can operate at relatively low temperatures, it can be used in situations where conventional thermal processing may damage the material being treated.

In healthcare, cold plasma is being investigated and adopted for wound management, infection control, dentistry, dermatology, sterilization, and cancer treatment research. In industrial settings, its applications extend to surface modification, polymer processing, textiles, electronics, and food decontamination.

The technology's antimicrobial properties are particularly important as healthcare providers look for alternatives and complements to conventional infection-control approaches. Growing hospital-acquired infection concerns are therefore becoming a significant demand driver for cold plasma solutions. 

Wound Care Is Giving the Technology a Strong Healthcare Entry Point

Among medical applications, wound healing has emerged as the leading use of cold plasma. The technology can support wound management through antimicrobial activity, reduction of infection risks, and stimulation of processes associated with tissue regeneration.

Grand View Research reports that the wound healing segment accounted for 35.3% of global revenue in 2025. The growing incidence of chronic wounds, including those associated with diabetes, vascular diseases, and pressure ulcers, is increasing the need for innovative treatment approaches. Cold plasma's ability to address microbial contamination while supporting the wound-healing environment is helping establish its position in advanced wound care. 

Cancer treatment is another emerging area. Although the application remains at a developing stage, research into plasma-based cancer therapies is attracting attention because cold plasma can generate reactive species that may interact selectively with cancer cells. The cancer treatment segment is projected to grow at a CAGR of 15.4% during the forecast period, according to GVR. 

Atmospheric Pressure Systems Lead the Technology Landscape

Cold plasma technologies can broadly operate under low-pressure or atmospheric-pressure conditions. Atmospheric pressure systems have an important advantage because they can operate under ambient conditions without requiring complex vacuum environments.

The atmospheric pressure cold plasma segment accounted for a 63.7% revenue share in 2025, making it the leading pressure segment. Its versatility across wound treatment, sterilization, and infection-control applications is supporting adoption in healthcare facilities and other environments. 

Low-pressure cold plasma is also gaining ground. GVR projects the segment to expand at a 13.9% CAGR during the forecast period. Its controlled operating environment makes it suitable for selected sterilization, wound-healing, and infection-control applications.

The Opportunity Extends Beyond Healthcare

Healthcare may currently provide some of the most visible applications, but cold plasma has a much wider industrial footprint. Food companies are exploring plasma-based approaches for decontamination, while textile manufacturers are using plasma treatment to modify surfaces and improve material characteristics.

Electronics and semiconductor manufacturing represents another important opportunity. Plasma treatment can modify material surfaces without relying solely on conventional chemical processes. This is particularly relevant as manufacturers seek more precise and efficient processing techniques.

Food safety is also becoming increasingly important. Cold plasma can help address microbial contamination while reducing dependence on certain chemical treatments. This supports demand for technologies that combine effective processing with lower environmental impact.

Regional Growth Is Broadening

North America currently leads the global industry. The region accounted for 40.4% of global revenue in 2025, supported by technological innovation, healthcare spending, research activity, and the presence of established industry participants. The U.S. alone represented 85.0% of North America's revenue in 2025. 

Asia Pacific is emerging as an especially dynamic growth center. The regional industry is projected to expand at a 15.6% CAGR over the forecast period. Growing electronics manufacturing, polymer production, food processing, and healthcare requirements are contributing to demand. China is particularly important because of its expanding semiconductor, electronics, healthcare, and food-processing industries.

Mexico is another developing opportunity, with GVR projecting a 12.4% CAGR from 2026 to 2033. Demand is being supported by applications involving electronics, packaging, and food decontamination. 

Looking for more specific insights? Customize this report to suite your business needs

Investment and Adoption Challenges

Despite its strong growth outlook, cold plasma technology still faces barriers to broader commercialization. One of the most significant is the high initial investment required for advanced systems. GVR notes that cold plasma generation systems used in healthcare can cost from tens of thousands to more than USD 500,000, creating affordability challenges for smaller healthcare providers. 

Regulatory requirements are another consideration, particularly for medical applications. Plasma-based devices must demonstrate safety and therapeutic effectiveness before gaining approval, which can lengthen development and commercialization timelines. Companies must therefore balance technological innovation with clinical validation, regulatory compliance, and cost management.

Companies Advancing Cold Plasma Technology

The competitive landscape includes specialized medical-device manufacturers, plasma technology companies, and industrial technology providers. Key companies profiled by Grand View Research include Apyx Medical, neoplas med GmbH, Adtec Healthcare Limited, terraplasma GmbH, CINOGY System GmbH, Plasmacure, relyon plasma GmbH, and US Medical Innovations. 

Recent investments and collaborations also indicate increasing commercial interest. In July 2025, Adtec secured USD 12 million in strategic investment from AIPO Fund and SG Biomedical to support global expansion and development of a next-generation cold plasma medical device. 

What the Future Could Look Like

The cold plasma industry is entering a period in which healthcare innovation and industrial processing requirements are converging. Wound care and infection control are likely to remain important growth areas, while cancer treatment research, food safety, electronics, textiles, and surface modification provide additional opportunities.

With the industry projected to reach USD 495.9 million by 2033, continued advances in plasma generation, portable systems, medical validation, and industrial integration could help move cold plasma from specialized applications into a wider range of commercial and clinical environments.